Similarly, following the concept that restoring/inducing p53 may provide beneficial therapeutic results for infectious diseases, a group of the Georgetown University has proposed a TP53 gene therapy approach for patients affected by COVID-19, hypothesizing the repurposing of the SGT-53 agent, an immunoliposome carrying a plasmid vector for TP53 expression, currently in phase II human trials for pancreatic cancer (8). The gene discussed is TP53; the disease is familial pancreatic carcinoma.